Healthcare & life sciences

November 2024  |  SPECIAL REPORT: HEALTHCARE & LIFE SCIENCES

Financier Worldwide Magazine

November 2024 Issue

Q&A: Private equity and M&A in the healthcare sector

The multibillion-dollar deals over the last year or so clearly demonstrate private equity’s appetite for the healthcare space. FW discusses private equity and M&A in the healthcare sector with Frank Aquilla at Sullivan & Cromwell LLP.

Recent and upcoming trends in life sciences M&A and R&D

Sheppard Mullin Richter & Hampton LLP Converging trends have put pressure on companies traditionally focused on R&D to invest in M&A activity and new technologies in an effort to innovate in the face of new challenges.

IP and business: two sides of the same strategy

Symbiosis IP Understanding the value of IP is crucial in order to explore how this may complement, or even drive, commercial strategy and future research.

Recent judgments from the EU’s top court narrow the scope for patent settlement agreements

Skadden, Arps, Slate, Meagher & Flom LLP The Court of Justice of the European Union’s ruling expands the scope of what constitutes a problematic patent settlement agreement under European Union competition law.

Smallest saleable patent-practicing unit in life sciences disputes

Charles River Associates The smallest saleable patent-practicing unit is often at issue in patent disputes relating to electronic devices and may, increasingly, be applicable to the calculation of patent damages relating to combination products in the life sciences sector.

Mitigating counterparty bankruptcy risk in partnering transactions

Davis Polk & Wardwell LLP It has never been more important to address counterparty bankruptcy risk when engaging in a partnering transaction with a pharmaceutical or biotechnology company.

Competition issues arising from AI in the life sciences sector

Norton Rose Fulbright LLP Competition authorities are monitoring developments and seeking to understand the dynamics of new AI-related markets, to ensure that they are able to intervene when appropriate, if competition concerns develop.

CONTRIBUTORS

Charles River Associates

Davis Polk & Wardwell LLP

Norton Rose Fulbright LLP

Sheppard Mullin Richter & Hampton LLP

Skadden, Arps, Slate, Meagher & Flom LLP

Sullivan & Cromwell LLP

Symbiosis IP

©2001-2024 Financier Worldwide Ltd. All rights reserved. Any statements expressed on this website are understood to be general opinions and should not be relied upon as legal, financial or any other form of professional advice. Opinions expressed do not necessarily represent the views of the authors’ current or previous employers, or clients. The publisher, authors and authors' firms are not responsible for any loss third parties may suffer in connection with information or materials presented on this website, or use of any such information or materials by any third parties.